Skip to main content

Immutep Limited (IMMP)

NASDAQ: IMMP · IEX Real-Time Price · USD
4.37 0.07 (1.63%)
Oct 21, 2021 12:01 PM EDT - Market open
Market Cap321.71M
Revenue (ttm)11.38M
Net Income (ttm)-9.29M
Shares Out74.82M
EPS (ttm)-0.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume84,699
Open4.26
Previous Close4.30
Day's Range4.22 - 4.45
52-Week Range1.65 - 7.95
Beta1.46
AnalystsBuy
Price Target6.50 (+48.7%)
Est. Earnings Daten/a

About IMMP

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-smal...

IndustryBiotechnology
CEOMarc Voigt
CountryAustralia
Stock ExchangeNASDAQ
Ticker SymbolIMMP
Full Company Profile

Financial Performance

In 2020, Immutep's revenue was 16.50 million, an increase of 120.31% compared to the previous year's 7.49 million. Losses were -13.47 million, -26.58% less than in 2019.

Financial numbers in millions AUDFinancial Statements

Analyst Forecast

According to 2 analysts, the average rating for Immutep stock is "Buy." The 12-month stock price forecast is 6.50, which is an increase of 48.74% from the latest price.

Price Target
$6.50
(48.74% upside)
Analyst Consensus: Buy

News

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

SYDNEY, AUSTRALIA, Sept. 29, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatme...

3 weeks ago - GlobeNewsWire

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

SYDNEY, Australia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...

1 month ago - GlobeNewsWire

Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002

Sydney, Sept. 01, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 1 September 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 re...

1 month ago - GlobeNewsWire

Immutep's Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to advise its Chinese partner for eftilagi...

1 month ago - GlobeNewsWire

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

Sydney, Aug. 27, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. ZL201...

1 month ago - GlobeNewsWire

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

Sydney, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cance...

2 months ago - GlobeNewsWire

Immutep Shares Are Trading Higher On Green Signal To Start Efti Combo Trial In First-Line Head & Neck Cancer

Immutep Limited (NASDAQ: IMMP) has completed all the necessary steps with the FDA and has received institutional review board approval to commence its Phase 2b TACTI-003 trials in the U.S. Patient recru...

3 months ago - Benzinga

Immutep To Initiate Efti Triple Combination Therapy Trial In Solid Tumors, Launches $60M Placement

Immutep (NASDAQ: IMMP) will begin a Phase 1 trial to evaluate its lead product candidate, eftilagimod alpha (efti or IMP321), in conjunction with chemotherapy and anti-PD-1 therapy. The trial, named INS...

4 months ago - Benzinga

7 Reddit Penny Stocks to Buy if You Have $100 to Spare

Reddit penny stocks are full of risk and reward, which is why $100 won't hurt you, but it can reward you handsomely. The post 7 Reddit Penny Stocks to Buy if You Have $100 to Spare appeared first on Inv...

4 months ago - InvestorPlace

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

SYDNEY, AUSTRALIA, June 04, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...

4 months ago - GlobeNewsWire

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pat...

SYDNEY, AUSTRALIA, June 02, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer ...

4 months ago - GlobeNewsWire

Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors

Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT-005 trial in patients with solid tumors. The tri...

Other symbols:MRK
4 months ago - Benzinga

Immutep To Present At The Jefferies Virtual Healthcare Conference

SYDNEY, AUSTRALIA, May 25, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer an...

4 months ago - GlobeNewsWire

Immutep Stock Gains on Encouraging Data from Early-Stage Solid Cancer Studies

Immutep Limited (NASDAQ: IMMP) has announced that data from its TACTI-002 and INSIGHT-004 studies have been published in abstracts for the American Society of Clinical Oncology's 2021 Annual Meeting. Da...

5 months ago - Benzinga

Top Penny Stocks to Buy Now? 4 Big Movers to Watch Today

Are these the top penny stocks to buy in 2021? Take a look and decide for yourself The post Top Penny Stocks to Buy Now?

Other symbols:AEHRONTXUXIN
5 months ago - PennyStocks

7 Reddit Penny Stocks Promising to Cure Cancer

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on I...

5 months ago - InvestorPlace

Immutep Operational Update

Sydney, AUSTRALIA, May 07, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatment...

5 months ago - GlobeNewsWire

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual...

SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer an...

5 months ago - GlobeNewsWire

Immutep Receives A$1,155,055 R&D Tax Incentive

SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from t...

6 months ago - GlobeNewsWire

Why Immutep Limited Stock Popped Today

Investors liked the company's latest regulatory update.

6 months ago - The Motley Fool

VERY Stock: Is a VERY Big Mix-Up Causing Vericity to Skyrocket?

Vericity (VERY) stock is on the rise Thursday morning despite a lack of news for the company in what could be a mix-up for investors. The post VERY Stock: Is a VERY Big Mix-Up Causing Vericity to Skyroc...

Other symbols:GMEPLLVERYZM
6 months ago - InvestorPlace

What's Going On With APRE Stock And IMMP Stock Today?

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading higher after the company announced that it received FDA Orphan Drug Designation for its eprenetapopt for the treatment of acute myeloid leukemia....

Other symbols:APRE
6 months ago - Benzinga

IMMP Stock: The Big Patent News Boosting Immutep Today

IMMP stock is getting a boost in Thursday trading after European regulators gave one of its cancer antibodies a key patent. The post IMMP Stock: The Big Patent News Boosting Immutep Today appeared first...

6 months ago - InvestorPlace

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metast...

Sydney, AUSTRALIA, April 08, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...

6 months ago - GlobeNewsWire

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer,...

6 months ago - GlobeNewsWire